Portal de Periódicos da CAPES

In vitro production of bilirubin photoisomers by light irradiation using neoBLUE

2007; Wiley; Volume: 49; Issue: 3 Linguagem: Inglês

10.1111/j.1442-200x.2007.02379.x

1442-200X

Hitoshi Okada, TAE ABE, Yoko Etoh, Shuji Yoshino, Ikuko Kato, Takuma Iwaki, Kensuke Okubo, Saneyuki Yasuda, Kou Kawada, Takashi Kusaka, Masanori Namba, Tomoko Nishida, Tadashi Imai, Kenichi Isobe, Susumu Itoh,

Heme Oxygenase-1 and Carbon Monoxide

Abstract Background: The light‐emitting diode is used as one of the new light sources for phototherapy. NeoBLUE (Atom Medical, Tokyo, Japan) incorporates blue light‐emitting diodes for the treatment of neonatal hyperbilirubinemia. The authors compared the in vitro efficacy of neoBLUE with conventional phototherapy devices. Methods: The three light devices used included neoBLUE and two conventional phototherapy devices with six blue–white (BW) or six green (GR) fluorescent tubes. A bilirubin/human serum albumin solution (15 mg/dL) in 200 × 300 mm elliptical bag was irradiated with each three light device. The average light intensity of neoBLUE, BW and GR was 22.5, 10.2 and 2.6 μW/cm 2 per nm, respectively, for the irradiated area. Bilirubin photoisomers and native bilirubin were measured by high‐performance liquid chromatography. Results: In neoBLUE, BW and GR, the respective production rate of cyclobilirubin was 6.0, 3.7 and 3.9 × 10 −2 mg/dL/min, and the respective (4Z, 15E)‐bilirubin/(4Z, 15Z)‐bilirubin ratio after irradiation was 0.44, 0.33 and 0.12; the (4Z, 15Z)‐bilirubin reduction rate at 20 min after irradiation was 60, 68 and 82%, respectively. The reduction rate of (4Z, 15Z)‐bilirubin correlated with the (4Z, 15E)‐bilirubin/(4Z, 15Z)‐bilirubin ratio. Conclusion: Phototherapy using the neoBLUE under high level may be clinically more effective than therapy using the conventional light source from the results of the production rate of cyclobilirubin.